The FDA released a much-anticipated draft guidance on how makers of rare disease genetic medicines can leverage a platform ...
iECURE's ECUR-506 showed promising safety and efficacy in a Phase 1/2 study for neonatal-onset OTC deficiency, with no major safety issues. BMO Capital Markets upgraded Precision BioSciences to ...
- Publication describes how the unique qualities of ARCUS nucleases contribute to precise and efficient gene editing for gene insertion, single base editing, specific small and large deletions, and ...
Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results